March 18, 2026
Client
Example Biotech
[CLIENT COMPANY ADDRESS]
Jane Doe
Proposal for Example Biotech
Dear Example Biotech,
On behalf of Aragen, I am pleased to submit our comprehensive proposal request for Cell Line Development and manufacturing of AB-101 in CHO-GS. Our proposal has been carefully aligned to your technical and commercial requirements and currently covers 1 mapped work packages.
We have mapped our full proposal and timeline to correspond to your requested work packages, milestones, and deliverables. Our end-to-end workflow provides transparent, milestone-based pricing, detailed Gantt timelines, and coordinated partner activities where outsourced scope is required.
Reference template: Gene-to-GMP mAb in CHO-GS.
Proposal strengths:
- A fully integrated solution across research, development, and manufacturing tailored for mAb programs with 1 planned stages.
- A robust program management framework with milestone-based governance and schedule visibility through a weekly execution grid.
- A clear approach to intellectual property, data ownership, and operational transparency for stage-gated development.
- Transparent cost structure, including staged pricing and pass-through estimates for external services and materials.
- Integrated vendor oversight for optional outsourced fill-finish while maintaining the primary Aragen program cadence.
Proposal Snapshot
Proposal for Example Biotech
Cell Line Development of AB-101 in CHO-GS and cGMP manufacturing
Aragen Project Code: CD-XXXXX-XXX; PS-XXXXX-XXX; GMP-XXXXX-XXX***
March 18, 2026
Key Notes and Assumptions
- Aragen would execute cell line development and integrated downstream activities for AB-101 in CHO-GS.
- The current commercial and timeline view assumes a 50 L stage-gated batch strategy with aligned analytical and process-development handoffs.
- Material costs and outsourced activities remain non-binding until final vendor scope and the release/stability panel are confirmed.
- Where Aragen outsources the DP fill-finish, the packaged product is assumed to return for stability handling and coordinated release support.
Pricing summary:
Service, material, and outsource line items are aligned to the activated work packages.
| Task | Service Fee | Material Cost (non-binding estimate) | Outsource Fee (non-binding estimate) |
|---|---|---|---|
| Grand total | $0 | $0 | $0 |
Timeline: (please see Excel for higher resolution)
This preview mirrors the proposal’s weekly grid and will expand further in the exported document.
| Weeks | Task | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 |
|---|
Work plan for Stable CHO Cell Line Development
Aragen will host a project kick off meeting to confirm goals, project-specific requirements, timeline, communication protocol, and procedures for change. A process review for addressable events that may affect timeline or budget will be discussed and documented.
At agreed upon intervals during the conduct of the work, Aragen will communicate progress and updates through recurring meetings and written draft reports.
Flow chart of main steps of cell line development project
S.1 Work Plan for CLD:
IV. Others
All applicable taxes, including withholding taxes, will be borne by Example Biotech. Taxes are not included in the service or material cost estimates and will be invoiced as incurred.
There are no royalties, milestone payments, or other fees due Aragen other than the fee outlined in this proposal. Payments, once made, are non-refundable unless otherwise stated in the final agreement.
Aragen will use its reasonable best efforts to achieve the technical and timing goals described in the proposal, however achievement of those goals may not be within Aragen’s sole control and cannot be guaranteed.
Documentation generated as part of the scope will be provided in Aragen’s standard electronic formats unless otherwise agreed in writing.
For Example Biotech:
Signature
Name
Title
Date
For Aragen Bioscience, Inc.:
Signature
Name
Title
Date